FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> melanoma | MannKind

MannKind starts Phase II melanoma vax trial

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


MannKind is best known in the industry for its ongoing attempts to win approval of it's inhaled insulin drug Afrezza. The developer is waiting for a final FDA decision on the drug later this year, but in the meantime it's advancing its oncology portfolio with the initiation of a Phase II melanoma vaccine study.

The Phase II study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma. The drug was well-tolerated in a Phase I study, and generated immune responses. MannKind adds that it saw encouraging data from a subset of patients with disease localized to the lymphatic system. MannKind expects to complete the study in June 2012.

The company has a second vaccine--MKC1106-PP--in development. It's completed Phase I trials for treatment of solid tumor malignancies where the PRAME and PSMA tumor associated antigens are frequently expressed. In an interview with Seeking Alpha earlier this year, CEO Alfred Mann said that his company's vaccines have potential advantages over Dendereon's Provenge (for prostate cancer), noting that MannKind's vaccines are less expensive. He added that both MKC1106-MT and MKC1106-PP are at least three years from approval

- check out MannKind's release
- read the Seeking Alpha interview

Related Articles:
Afrezza - FDA's top 10 Blockbuster Decisions
MannKind looks to raise $110M
MannKind defies analysts skeptical of inhaled insulin drug

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about melanoma   MannKind  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.